Table 3.
Baseline Demographic and Clinical Characteristics and Outcome Measures for Influenza B
| Category | Influenza B | |||
|---|---|---|---|---|
| All | IC | IS | P | |
| (n = 166) | (n = 80) | (n = 86) | ||
| Age, median (IQR), y | 62 (49–73) | 68 (55–77) | 57 (47–65) | <.001 |
| Female gender, No. (%) | 82 (49.4) | 36 (45) | 46 (53.5) | .274 |
| Comorbidities, No. (%) | ||||
| Adipositas | 16 (9.6) | 8 (10) | 8 (9.3) | .879 |
| Diabetes | 35 (21.1) | 17 (21.3) | 18 (20.9) | .96 |
| Coronary artery disease | 34 (20.5) | 20 (25) | 14 (16.3) | .164 |
| Congestive heart failure | 37 (22.3) | 23 (28.7) | 14 (16.3) | .054 |
| COPD | 18 (10.8) | 10 (12.5) | 8 (9.3) | .508 |
| Asthma | 9 (5.4) | 3 (3.8) | 6 (7) | .359 |
| CF | 3 (1.8) | 1 (1.3) | 2 (2.3) | .603 |
| Chronic kidney disease | 60 (36.1) | 21 (26.3) | 39 (45.3) | .01 |
| Chronic renal replacement therapy | 10 (6) | 2 (2.5) | 8 (9.3) | .066 |
| Immunosuppression, No. (%) | 86 (51.8) | 0 (0) | 86 (100) | <.001 |
| HTX | 0 (0) | - | 0 (0) | |
| LuTX | 19 (11.4) | - | 19 (22.1) | |
| NTX | 17 (10.2) | - | 17 (19.8) | |
| LTX | 2 (1.2) | - | 2 (2.3) | |
| HSCT | 12 (7.2) | - | 12 (14) | |
| Cancer | 18 (10.8) | - | 17 (19.8) | |
| Rheumatoid disease | 17 (10.2) | - | 17 (19.8) | |
| AIDS | 2 (1.2) | - | 2 (2.3) | |
| Steroids baseline, No. (%) | 58 (34.9) | 1 (1.3) | 57 (66.3) | <.001 |
| Neuraminidase inhibitor, No. (%) | 67 (40.4) | 35 (43.8) | 32 (37.2) | .391 |
| Hospital admission, No. (%) | 133 (80.1) | 74 (92.5) | 59 (68.6) | <.001 |
| ICU admission, No. (%) | 21 (12.7) | 14 (17.5) | 7 (8.1) | .07 |
| Steroid pulse, No. (%) | 6 (3.6) | 4 (5) | 2 (2.3) | .356 |
| Invasive ventilation, No. (%) | 15 (9) | 11 (13.8) | 4 (4.7) | .041 |
| Norepinephrin, No. (%) | 15 (9) | 12 (15) | 3 (3.5) | .01 |
| Renal replacement therapy, No. (%) | 11 (6.6) | 8 (10) | 3 (3.5) | .092 |
| Antibiotic treatment, No. (%) | 64 (38.6) | 30 (37.5) | 34 (39.5) | .788 |
| Pneumonia, No. (%) | 61 (36.7) | 29 (36.3) | 23 (37.2) | .898 |
| Cardiac manifestation, No. (%) | 13 (7.8) | 12 (15) | 1 (1.2) | .001 |
| Aspergillus superinfection, No. (%) | 2 (1.2) | 0 (0) | 2 (2.3) | .17 |
| Extracorporeal life support systems, No. (%) | 10 (6) | 9 (11.3) | 1 (1.2) | .01 |
| Vv ECMO | 3 (1.8) | 2 (2.5) | 1 (1.2) | .518 |
| Va ECMO | 3 (1.8) | 3 (3.8) | 0 (0) | .07 |
| Impella | 4 (2.4) | 4 (5) | 0 (0) | .036 |
| Mortality, No. (%) | 10 (6) | 7 (8.8) | 3 (3.5) | .147 |
| ICU Mortality, No. (%) | 5 (23.8) | 4 (28.6) | 1 (14.3) | .429 |
Abbreviations: CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; HSCT, hematopoetic stem cell transplantation; HTX, heart transplantation; IC, immunocompetent patients; ICU, intensive care unit; IQR, interquartile range; IS, immunosuppressed patients; LTX, liver transplantation; LuTx, lung transplantation; NTX, kidney transplantation; Va ECMO, veno-arterial extracorporeal membrane oxygenation; Vv ECMO, veno-venous extracorporeal membrane oxygenation. Statistical significant P values are bolded.